The poster entitled: 'Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 (Tedopi) vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the
A high/high Immunoscore associated with high CD8 T-cell tumor infiltration, and a higher proportion of CD8 cells interacting with PD-L1 cells in a patient with a partial response;
Transcriptomic data have shown an activated macrophage pathway. High IFN-? and expanded immune gene signatures scores were observed in long-term surviving patients with secondary resistance to immune checkpoint blockade.
The Phase 3 clinical trial
The poster entitled: 'Long-term anti-tumor preclinical efficacy of an optimized anti-PD-1/IL-7 bifunctional antibody sustaining activation of progenitor stem-like CD8 TILs and disarming Treg suppressive activity' has described a monotherapy with BiCKI-IL-7, an anti-PD1/IL-7 bifunctional monoclonal antibody, that induces long-term survival, proliferation and responses without signs of exhaustion of T cells as well as robust in vivo anti-tumor memory response in different preclinical models.
Interestingly, targeting IL-7 on PD1+ tumor-specific T cells has shown to have a unique property in selectively inducing the proliferation and survival of TCF1+ (T Cell Factor 1) stem-like CD8 T cells in vitro in human T-cell exhaustion model and in vivo in mouse tumor model, avoiding exhaustion of stem tumor-reactive T cells and hence providing long-term anti-tumor memory.
TCF1+ PD1+ CD8 T cells, which express high level of IL-7R, have been broadly described these last years as T cells with potent stem-like properties promoting tumor control in response to vaccination or checkpoint blockade immunotherapy (Siddiqui I. et al. Immunity 2019;
Review Immunology 2021).
Poster #366 'Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the
Category: Clinical Trials Completed
Poster #794 'Long-term anti-tumor preclinical efficacy of an optimized anti PD-1/IL-7 bifunctional antibody sustaining activation of progenitor stem-like CD8 TILs and disarming Treg suppressive activity'
Category:
ABOUT
therapies to control the immune system for immuno-oncology and autoimmune diseases. The company's immunology research and development platform is focused on three areas: T-cell-based vaccination,
Vaccine platform
Tedopi (innovative combination of neoepitopes): the company's most advanced product; positive results for the Phase 3 trial (
In Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR.
In Phase 2 in ovary cancer, in combination with pembrolizumab (TEDOVA), sponsor ARCAGY-GINECO.
In Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT.
CoVepiT: a prophylactic second-generation vaccine against COVID-19, developed using SARS-CoV-2 optimized epitopes against multi variants. Positive preclinical and human ex vivo results. Voluntary and temporary Phase 1 enrollment suspension on-going (July 2021).
BI 765063 (OSE-172, anti-SIRP? mAb on CD47/ SIRP? pathway): developed in partnership with
CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the 'Don't Eat
Me' signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells.
BiCKI: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity.
Auto-immunity and inflammation platform
FR104 (anti-CD28 monoclonal antibody): Licensing partnership agreement with Veloxis in the organ transplant market; ongoing Phase 1/2 in renal transplant (sponsored by the
OSE-127/S95011 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with
OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.
Contact:
E: sylvie.detry@ose-immuno.com
T: +33 153 198 757
Investor
E: thomas.guillot@ose-immuno.com
T: +33 607 380 431
Media
E: darren@lifescicomms.com
T: +1 646 627 8387
French
FP2COM
E: fportejoie@fp2com.fr
T: +33 607 768 283
LifeSci
Advisors
E: gvanrenterghem@lifesciadvisors.com
T: +41 76 735 01 31
Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of
These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the
(C) 2021 Electronic News Publishing, source